M, Mongillo M. Cardiac sympathetic neurons provide trophic signal to the heart via β2-adrenoceptor-dependent regulation of proteolysis.
systemic manifestations including abnormalities in glucose and lipid metabolism, alterations in coagulation factors, hypertension, cardiovascular disease, depression, and impaired health-related quality of life.
Dilated cardiomyopathy is rarely associated with CS, with only few single cases previously reported in English literature. 1 Histological changes and molecular pathways involved in CS-dilated cardiomyopathy are poorly understood, whereas structural outcome after cardiac recovery is unknown.
We reported a research case of CS dilated cardiomyopathy in which noninvasive and invasive cardiac studies at baseline and follow-up were obtained after written patient consent.
A 63-year-old woman had CS caused by adrenal adenoma. Echocardiographic left ventricular (LV) end-diastolic diameter, ejection fraction and maximal wall thickness, endomyocardial biopsy with assessment of cardiomyocyte diameter, % myofibrillolysis area, myocardial fibrosis and cell death, and myocardial atrogin-1 were evaluated at presentation and after 1-year cortisol normalization with adrenalectomy. At presentation, LV was hypertrophied, dilated, and severely hypokinetic (ejection fraction<24%; Movies I and II in the Data Supplement). After adrenalectomy, LV end-diastolic diameter reduced from 61 to 51 mm, maximal wall thickness from 12 to 8 mm, whereas LV ejection fraction rose from 24% to 50% (Figure 1 ; Movies III and IV in the Data Supplement). Cell diameter reduced from 28.5 to 15.5 μm, myocardial fibrosis declined from 11.7% to 3.0%, and myofibrillolysis cell area reduced from 60% to 21% ( Figure 2 ). Cell death was comparable with idiopathic dilated cardiomyopathy. Atrogin-1 mRNA was at presentation 30× higher than normal controls, normalized after adrenalectomy and correlated inversely with LV ejection fraction.
The present report comparing histological, ultrastructural, and molecular parameters in endomyocardial biopsy samples from a patient with CS cardiomyopathy, before and after cortisol normalization, shows that cardiomyocyte hypertrophy, myofibrillolysis, and myocardial fibrosis are the main structural abnormalities and that they revert completely at 1-year follow-up from adrenalectomy (Figure 2) . Mechanisms involved in cell hypertrophy include pressure overload, a glucocorticoid-mediated increase of angiotensin-II and an enhanced responsiveness of cardiomyocytes to angiotensin-II. Cell myofibrillolysis strictly correlates with myocardial expression of atrogin-1, which is increased >30× control values during failing state and normalizes after cardiac recovery being associated to decrease of myofibrillolysis cell area from 60% to 21%. In humans, these data confirm the atrophic effects of glucocorticoids on skeletal 2 and cardiac 3 muscle obtained in experimental models. The molecular pathway involved includes activation of Foxo transcription factors, overexpression of atrogin-1 and ubiquitin promoting proteasome proteolysis of endogenous contractile elements.
Myocardial fibrosis derives from a direct glucocorticoid stimulation of fibroblast activity, likely through Smad and transforming growth factor β-1 pathway, and reducing in our CS patient from 11.7% to 3.0% after adrenalectomy confirming the data obtained by speckle tracking echocardiography. 4 In conclusion, CS-dilated cardiomyopathy is a reversible entity induced by high levels glucocorticoids. It is characterized by cell hypertrophy, myofibrillolysis, and myocardial fibrosis that revert after cortisol normalization. Atrogin-1 activation has a major pathogenetic role.
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